Creative Biolabs Accelerates Metabolic Disease Drug Discovery with Deep Learning for Multi-Receptor Agonist Design

SHIRLEY, NY, June 18, 2026 /24-7PressRelease/ — Driven by the clinical success of GLP-1 therapies, the pharmaceutical industry is aggressively pursuing dual and triple-receptor agonists (such as GLP-1/GIP/GCGR combinations) to combat obesity and type 2 diabetes. However, optimizing multi-target affinity while maintaining metabolic stability presents a formidable computational challenge. Addressing this bottleneck, Creative Biolabs has upgraded its AI-driven functional protein solutions, empowering industrial biotechnology clients to rapidly screen millions of peptide sequences and accelerate the development of next-generation metabolic therapeutics.

Overcoming the Bottleneck in Polypharmacology
Traditional iterative optimization of polypharmacological peptides is highly labor-intensive, often requiring years of trial and error to balance the activation ratios of multiple receptors. Creative Biolabs leverages proprietary deep learning algorithms to conduct the computational design of multi-receptor agonists. By simulating receptor-ligand interactions within a high-throughput virtual environment, the platform identifies “single-shot” molecules capable of simultaneously and precisely activating multiple relevant biological pathways. This approach drastically compresses the timeline from hit identification to lead optimization, reducing typical research cycles to a mere 2 to 14 weeks.

Technical Analysis: Resolving Half-Life and Data Quality Challenges
A persistent industry challenge—and a frequent concern among pre-clinical developers—is how to prevent the rapid enzymatic degradation of peptide drugs in vivo. Creative Biolabs’ AI infrastructure addresses this by calculating and systematically eliminating vulnerable sequence sites, engineering ultra-long-acting profiles that reduce patient dosing frequency.

Furthermore, machine learning models in drug discovery frequently suffer from the “garbage in, garbage out” dilemma. To counter this, Creative Biolabs relies on high-fidelity pharmacological dataset training. By utilizing carefully curated, function-first data, the platform accurately predicts ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties early in the pipeline. This ensures that the generated sequences are not only highly potent but also devoid of severe off-target toxicity or unwanted immunogenicity.

Expanding Chemical Space via Precision Modulation
Beyond traditional orthosteric sites, next-generation metabolic regulators demand exquisite selectivity to prevent adverse effects. The platform integrates molecular dynamics (MD) simulations to enable the rational design of ligands targeting hidden binding pockets. This structural biology approach allows pharmaceutical developers to fine-tune receptor activity through precise allosteric modulation, avoiding the overstimulation of highly homologous protein families and bypassing resistance mechanisms.

“Industrial clients require more than just theoretical binding affinity; they demand manufacturable, highly stable molecules with guaranteed functional activity in biological assays,” stated the director of computational biology at Creative Biolabs. “Our deep learning pipelines transition multi-receptor sequence design from a process of serendipity to a highly predictable, automated workflow.”

Pharmaceutical partners utilizing these proprietary AI pipelines have reported a significant reduction in design-test-learn cycles. Early adopters highlight the platform’s high predictive accuracy and the comprehensive nature of the deliverables, which bridge the gap between in silico predictions and in vitro success.

Biotechnology firms and pharmaceutical companies developing pipeline assets for complex metabolic disorders are encouraged to implement these advanced computational workflows. To review technical specifications or request a specialized project consultation, please visit Creative Biolabs’ official platform.

—
For the original version of this press release, please visit 24-7PressRelease.com here